Strona główna・Stock List・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Closed

SectorHealthcare

103.05 20.03

Buy Sell

Overview

Share price change

24h

Current

Min

101.15

Max

103.27

Key metrics
By Trading Economics
Income	292M 150M
Sales	-75M 377M
P/E Sector Avg	28.867 68.51
EPS	1.221
Profit margin	39.832
Employees	423
EBITDA	-62M 220M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	-9.09% downside

Market Stats
By TradingEconomics
Market Cap	2.1B 9.8B
Previous open	83.02
Previous close	103.05

News Sentiment

By Acuity

17%

83%

31 / 340 Ranking in Healthcare

Halozyme Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 sie 2026, 23:21 UTC

News

Halozyme Therapeutics reported strong Q2 earnings and raised guidance, yet shares are trading lower in after-market hours following notable weakness.

6 sie 2026, 23:51 UTC

News

Social Media

Halozyme Therapeutics shares advanced in after-market trading following record second-quarter results, with revenue rising to $481 million and guidance increased for the year.

5 sie 2026, 22:16 UTC

Halozyme Therapeutics shares are lower in after-market trading, reflecting broader market pressures amid mixed sentiment from geopolitical developments and weak employment data.

4 sie 2026, 19:22 UTC

News

Halozyme Therapeutics is higher today, driven by 39.1% revenue growth from its ENHANZE technology, which enhances market share and earnings performance.

3 sie 2026, 19:46 UTC

Halozyme Therapeutics Inc. shares are lower today, despite earlier gains, amid a broader market rally following a significant drop in oil prices.

31 lip 2026, 20:06 UTC

Shares of Halozyme Therapeutics are lower today, reflecting broader market trends amid rising U.S. Treasury yields and crude oil prices influencing inflation concerns.

30 lip 2026, 19:58 UTC

Halozyme Therapeutics Inc shares are higher, reflecting a broader recovery in technology stocks amid improved market sentiment. The stock remains near its one-month range.

29 lip 2026, 19:27 UTC

Social Media

Halozyme shares are higher today, despite earlier pulling back. Recent commentary raises concerns about future performance and potential writedowns from acquisitions.

28 lip 2026, 20:03 UTC

Halozyme Therapeutics Inc. is trading higher, benefiting from a broader upward trend in biotechnology stocks, despite a pullback earlier in the session.

27 lip 2026, 19:46 UTC

Shares of Halozyme Therapeutics Inc. are lower today, continuing a decline since Friday. Broader market sentiment is affected by a drop in crude oil prices.

24 lip 2026, 20:07 UTC

News

Halozyme Therapeutics is gaining traction as shares rise, supported by strong cash flow margins and revenue growth. The stock is currently priced at $80.60 per share.

22 lip 2026, 19:35 UTC

Halozyme Therapeutics shares are lower today, despite an earlier peak gain. The decline follows a drop since Tuesday's close amid rising crude oil prices.

Peer Comparison

Price change

Halozyme Therapeutics Inc Forecast

Price Target

By TipRanks

-9.09% downside

12 Months Forecast

Average 93.75 USD -9.09%

High 115 USD

Low 57 USD

Based on 8 Wall Street analysts offering 12 month price targets forHalozyme Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Halozyme Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

31 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.